Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 8 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total

Not Applicable (1)

P 2 (1)

P 4 (1)

Trial Status

Completed4

Recruiting2

Active Not Recruiting1

Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06353529Phase 4RecruitingPrimary

Postop Pain Management in Pituitary Tumour Patients

NCT04042753Phase 2Active Not RecruitingPrimary

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

NCT04572139CompletedPrimary

Age-related Differences in Response to Pituitary Stimulation Tests

NCT05601141RecruitingPrimary

Clinics and Epidemiology of Pituitary Diseases in Modena Area Population

NCT06607198Not Yet RecruitingPrimary

Clinical-pathological Evaluation of Pit-NETs

NCT03636568Not ApplicableCompleted

Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)

NCT04119206Completed

Tolvaptan Versus Fluid Restriction in SIADH

NCT01705821Completed

Forces During Skull Base Surgery

Showing all 8 trials

Pituitary